Avodart (Dutasteride) in Adults 65 and Older: School, Work, and Daily Activity Considerations

Does dutasteride limit driving, work, school or exercise?

The Avodart prescribing information lists these warnings and precautions: PSA interpretation, high-grade prostate cancer risk, evaluation for other urological conditions, handling by pregnant women, blood donation, and effects on semen characteristics [1]. The label's dose is one 0.5 mg capsule once daily, swallowed whole and not chewed or opened, with or without food [1].

CombAT was a 4-year randomized double-blind study of 4,844 men aged 50 and older with BPH, comparing dutasteride 0.5 mg, tamsulosin 0.4 mg and the two together [3]. Its participants were aged 49 to 88 with a mean age of 66 [1]. The label's table for the first six months of that study lists dizziness in 1.1% of men on the combination, 0.5% on dutasteride alone and 0.9% on tamsulosin alone [1]. The same period shows ejaculation disorders in 7.8% of the combination arm versus 1.0% on dutasteride and 2.2% on tamsulosin, impotence 5.4% versus 4.0% and 2.6%, and decreased libido 4.5% versus 3.1% and 2.0% [1].

Adverse reactions listed in the label

In the three pooled two-year placebo-controlled BPH trials (2,167 men on Avodart, 2,158 on placebo, mean age 66), the label reports for months 0 to 6: impotence 4.7% versus 1.7%, decreased libido 3.0% versus 1.4%, ejaculation disorders 1.4% versus 0.5%, and breast disorders (enlargement or tenderness) 0.5% versus 0.2% [1]. Rates fell after the first six months except breast disorders, which were 1.1% versus 0.3% at months 13 to 18 [1]. The label notes that these sexual adverse reactions may persist after discontinuation and that the role of dutasteride in that persistence is unknown [1].

Postmarketing reports named in the label include hypersensitivity reactions such as rash, itching, hives and angioedema, male breast cancer, depressed mood, and testicular pain and swelling [1].

Mood in men over 65

Depressed mood appears in the Avodart label's postmarketing list [1]. A Swedish register-based cohort included 2,236,876 men aged 50 to 90, of whom 8,774 started dutasteride. The hazard ratio for depression among dutasteride starters was 1.68 (95% CI 1.43 to 1.96) and stayed constant over time, while suicide was not associated (hazard ratio 0.98, 95% CI 0.62 to 1.54) [4]. That study was observational and most dutasteride starters were older men with BPH, so it reports an association rather than a cause [4].

Half-life and blood donation

Dutasteride's terminal half-life is about 5 weeks at steady state. The label puts the drug at 65% of steady state after one month and about 90% after three months, and serum levels stay above 0.1 ng/mL for up to 4 to 6 months after the last dose [1]. The label says men being treated with Avodart should not donate blood until at least 6 months have passed since the last dose, to prevent giving dutasteride to a pregnant transfusion recipient [1].

PSA testing

The label says dutasteride reduces serum PSA by about 50% within 3 to 6 months, that a new PSA baseline should be established at least 3 months after starting and monitored periodically after that, and that an isolated PSA in a man treated for 3 months or more is doubled for comparison with normal values in untreated men [1]. Any confirmed increase from the lowest on-treatment value may signal prostate cancer and should be evaluated even if still within the normal range for untreated men. Percent free PSA stays constant, adding tamsulosin changes PSA the same way as dutasteride alone, and the label notes that noncompliance may also affect PSA results [1].

The label also warns of an increased risk of high-grade prostate cancer: in the 4-year REDUCE trial, Gleason 8 to 10 cancers were found in 1.0% of men on Avodart versus 0.5% on placebo [1].

Sport, competition and gym time

Dutasteride and finasteride are not named in the text of the WADA 2026 Prohibited List [2].